KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Accumulated Expenses (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Other Accumulated Expenses for 12 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses fell 81.33% year-over-year to $3.2 million, compared with a TTM value of $3.2 million through Dec 2025, down 81.33%, and an annual FY2025 reading of $3.2 million, down 81.33% over the prior year.
  • Other Accumulated Expenses was $3.2 million for Q4 2025 at Travere Therapeutics, down from $5.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $17.1 million in Q4 2024 and bottomed at $3.2 million in Q4 2025.
  • Average Other Accumulated Expenses over 5 years is $7.5 million, with a median of $5.7 million recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses surged 226.64% in 2024, then tumbled 81.33% in 2025.
  • Year by year, Other Accumulated Expenses stood at $6.2 million in 2021, then decreased by 7.53% to $5.7 million in 2022, then fell by 8.48% to $5.2 million in 2023, then soared by 226.64% to $17.1 million in 2024, then crashed by 81.33% to $3.2 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for TVTX at $3.2 million in Q4 2025, $5.4 million in Q3 2025, and $14.3 million in Q2 2025.